Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Mar 13

ABSTRACT

Related Questions

In a patient with metastatic HR+/HER2- breast cancer who progressed on adjuvant hormonal therapy, do you start fulvestrant + CDK4/6i or do you wait for NGS testing to determine eligibility for targeted agents such as elacestrant or PIK3CA inhibitors?

New answer by Medical Oncologist at Cleveland Clinic (March 26, 2024)

I typically order upfront NGS testing at the time of HR+/HER2- metastatic breast cancer diagnosis with the idea that I will have the PIK3CA mutation information already availa...

Related Questions

Why do I have to sign in?